期刊
FRONTIERS IN PHARMACOLOGY
卷 14, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2023.1249492
关键词
anemia; chronic kidney disease; daprodustat; HIF; renal disease
The FDA has approved daprodustat as the first oral treatment option for anemia in CKD dialysis patients. Clinical trials have shown its efficacy and safety, non-inferior to darbepoetin and potentially reducing IV iron usage. Daprodustat also holds potential for treating anemia in non-dialysis patients with CKD and for patients with both renal anemia and heart failure, pending further research.
The United States FDA has approved daprodustat (DPD) as the first oral treatment option for anemia due to chronic kidney disease (CKD) in dialysis patients. Clinical trials have demonstrated DPD's efficacy and safety, showing non-inferiority to darbepoetin and suggesting reduced IV iron usage. DPD also holds potential for treating chronic kidney disease anemia in non-dialysis patients and may have benefits for patients with coexisting renal anemia and heart failure, pending further research and trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据